NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)

Completed · Phase 2 · Has a placebo group

Conditions studied: Urethritis

In brief

This study will look at the safety, effectiveness, and tolerability of combination medications for the initial treatment of non-gonococcal urethritis (NGU). NGU is inflammation of the tube that carries urine from the bladder. NGU is caused by bacteria that may be passed from person to person during sex. This study will compare the 2 currently recommended NGU treatments, doxycycline and azithromycin, taken with tinidazole (another medication to treat certain sexually transmitted infections). Tinidazole used with doxycycline or azithromycin may cure NGU better than when doxycycline or azithromycin is used alone. Study participants will be 300 men ages 16-45 years with NGU attending sexually transmitted disease clinics in Birmingham, AL; New Orleans, LA; Durham, NC; and Baltimore, MD. Study participation will last 7 weeks and involve 3 visits. At each visit, participants will provide a urine sample, have 2 urethral swabs, and have their urethra checked for discharge indicating infection.

Key facts

Study ID

NCT00322465

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

305

Starts

2006-11-01

Expected to finish

2009-04-01

Last updated by the study team

2019-03-01

Who can join

Age: 16 and older, up to 45. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male, 16 to 45 years old.
• Symptoms of non-gonococcal urethritis (NGU), including urethral discharge and/or dysuria for less than or equal to 14 days, or urethral discharge on exam.
• Urethral smear with greater than or equal to 5 polymorphonuclear leukocytes (PMNs) per 3-5 oil immersion fields.
• Willing to abstain from sexual intercourse or use condoms during the study.
• Willingness to provide written consent.

You may not qualify if…

• Presence of gonorrhea at baseline visit.
• History of recurrent non-gonococcal urethritis (NGU) (3 or more episodes in the prior year) or history of recent NGU (within past 30 days).
• Signs or symptoms of epididymitis or prostatitis.
• Known allergy to or intolerance of tinidazole, tetracyclines, macrolides or metronidazole.
• History of photosensitivity related to doxycycline use.
• Received systemic antibiotics within 30 days of study enrollment.
• Unwillingness to abstain from alcohol for 24 hours after enrollment.
• Serious underlying infection, including known HIV or other primary or secondary immunosuppression.
• Concomitant infection, which requires antimicrobial therapy.
• History of mental illness, which would preclude responsible participation in the study.
• Current drug abuse that might affect ability to follow the protocol.
• Previously enrolled in this study.
• Men who have sex with men, due to different microbiology of NGU.
• Voided within the previous hour.
• Ingested alcohol within the past 8 hours.
• Subject requires concurrent lithium, anticoagulation therapy, or antabuse.

Where it is running

• University of Alabama Hospital - Infectious Diseases — Birmingham, Alabama, United States
• Delgado Personal Health Center — New Orleans, Louisiana, United States
• Johns Hopkins Hospital - Emergency Medicine — Baltimore, Maryland, United States
• University of North Carolina School of Medicine - Center for Infectious Diseases — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.